Clinical Trial Update: A Study to Evaluate the Pharmacokinetics, Safety, Tolerability, and Antiviral Activity of Rilpivirine (TMC278) in Human Immunodeficiency Virus Infected Adolescents and Children Aged Greater Than or Equal to 6 Years [Phase 2]

View source ↗

Summary

Phase 2 pediatric study evaluating pharmacokinetics, safety, tolerability, and antiviral activity of rilpivirine in HIV-1–infected children aged 6 years and old…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Human Immunodeficiency Virus Infection

Drugs mentioned

• rilpivirine (rilpivirine)

Snippet

Sponsor: Janssen Sciences Ireland UC | Conditions: HIV-1 | Phase 2 | Status: COMPLETED | Results posted: 2024-06-25